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Abstract
Background: In Egypt, Wilson disease seems to be under diagnosed and clinical data on large cohorts are limited.
The aim of this study is to highlight the clinical, laboratory and genetic characteristics of this disease in our
pediatric population as well as to report our experience with both treatment options and outcome.
Methods: The study included 77 patients from 50 unrelated families (62 were followed up for a mean period of
58.9 ± 6.4 months and 27 were asymptomatic siblings). Data were collected retrospectively by record analysis and
patient interviews. Diagnosis was confirmed by sequencing of the ATP7B gene in 64 patients
Results: Our patients had unique characteristics compared to other populations. They had a younger age of onset
(median: 10 years), higher prevalence of Kayser-Fleischer rings (97.6% in the symptomatic patients), low
ceruloplasmin (93.5%), high rate of parental consanguinity (78.9%) as well as a more severe course. 71.42% of those
on long term D-penicillamine improved or were stable during the follow up with severe side effects occurring in
only 11.5%. Preemptive treatment with zinc monotherapy was an effective non-toxic alternative to D-penicillamine.
Homozygous mutations were found in 85.7%, yet limited by the large number of mutations detected, it was
difficult to find genotype-phenotype correlations. Missense mutations were the most common while protein-
truncating mutations resulted in a more severe course with higher incidence of acute liver failure and neurological
symptoms.
Conclusions: Egyptian children with Wilson disease present with early Kayser-Fleischer rings and early onset of
liver and neurological disease. The mutational spectrum identified differs from that observed in other countries.
The high rate of homozygous mutations (reflecting the high rate of consanguinity) may potentially offer further
insights on genotype-phenotype correlation
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Background
Wilson’s disease (WD) is a rare autosomal recessive dis-
order of copper metabolism, with a prevalence of about
1 in 30 000 people. Its frequency increases in popula-
tions where consanguinity is more common [1]. It is
characterized by decreased biliary copper excretion and
defective incorporation of copper into ceruloplasmin,
leading to copper accumulation in different tissues
mainly the liver, brain and kidneys [2].
WD typically begins with a pre-symptomatic period,
during which copper accumulation in the liver causes
subclinical hepatitis and progresses to liver cirrhosis and
development of neuropsychiatric symptoms. The type of
hepatic and neurological symptoms can be highly vari-
able. It may also present as fulminant hepatic failure
with an associated Coomb’s-negative hemolytic anemia
and acute renal failure [3]. If untreated WD causes pro-
gressive fatal liver and brain damage [4] and therefore,
early recognition and treatment is required.
In 1993, the WD gene, ATP7B, was cloned. This gene
codes for a membrane-bound copper -transporting
ATPase expressed primarily in the liver [5,6]. More than
400 mutations within the ATP7B have been identified so
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tics are increasingly available for clinical use, in practice
their use is very limited.
The diagnosis of WD is based on the results of several
clinical and biochemical tests, each has its limitations,
and only the combination of clinical, biochemical and
genetic tests provides a powerful and reliable tool for
the diagnosis [3].
Zinc sulfate and D-penicillamine (D-PCA) have both
proved to be clinically effective in the treatment of WD,
but zinc sulfate offers the advantage of having a very
low toxicity, especially in the case of neurological invol-
vement. For asymptomatic or pre-symptomatic patients,
zinc salts or maintenance dosages of chelating agents
may be used [7].
In Egypt, where viral hepatitis (HCV, HBV) is by far
the major player in the field of liver disease, WD seems
to be under diagnosed and clinical data on large cohorts
are limited owing to its low frequency, being a rare dis-
ease. The aim of this study was to highlight the clinical,
laboratory and genetic characteristics of WD in our
pediatric population as well as to report our experience
with both treatment options and outcome aiming at
increasing awareness about diagnosis and management.
Based on the mutational spectrum rapid screening
approaches may be applied for Egypt in the future.
Methods
The study included 77 WD patients (75 children and 2
adult cousins) (43 males and 34 females), 62 of whom
(34 males and 28 females) were followed up for a mean
period of 58.9 ± 6.4 months. Patients were from 50
unrelated families presenting to Yassin Abdelghaffar
Charity Center for liver disease and research and the
Pediatric Hepatology clinic, Ain Shams University (both
are tertiary referral centers) from 1992 to 2009. One or
more authors cared for all patients. Data were collected
retrospectively by record analysis and patient interviews.
The study was approved by the ethical committee of
both Yassin Abdelghaffar Charity Center for liver dis-
ease and research and Ain Shams University and
informed consent for inclusion in the study was
obtained from parents of children.
Initial diagnosis of WD was made if the patient had
hepatic and/or neurologic disease in addition to at least
two of the following six criteria (adapted and modified
from Dhawan et al., 2005)[8]:
1- Positive family history of WD
2- Low ceruloplasmin level (< 20 mg%)
3- Presence of Kayser-Fleischer (KF) ring
4- Liver biopsy suggestive of WD (positive staining
of copper associated protein (rhodanine or orcein
stain), presence of glycogenated nuclei, micro- or
macrovesicular steatosis, or ultra structural changes
defined by electron microscopy) as measurement of
liver copper is not available in Egypt.
5- Elevated baseline 24-hour urinary copper excre-
tion (more than 100 μg/24 hours or more than1600
μg/24 hours after D-PCA challenge test).
6- Coomb’s negative hemolytic anemia
According to the type of presentation, symptomatic
patients were classified into three groups:
- Group 1 (G1): Patients with hepatic presentation
defined as presence at time of diagnosis of exclu-
sively hepatic symptoms and signs in the absence of
neurological symptoms and signs as confirmed by
careful neurological examination (n = 35).
- Group 2 (G2): Patients with neurological presenta-
tion defined as the presence of neurological symp-
toms and the absence of hepatic symptoms at the
time of diagnosis (n = 6).
- Group 3 (G3): Patients with combined presentation
defined as the appearance of neurological manifesta-
tions in a patient with hepatic disease within the
first 6 months of the initial diagnosis (n = 9).
Brothers and sisters of all patients diagnosed with WD
were screened for the disease by being subjected to full
history taking, physical examination, serum ceruloplas-
min, liver function tests, slit lamp examination for KF
ring, and molecular testing. Those who had no symp-
toms at presentation and were discovered to have WD
during screening of family members of the index case
comprised Group 4 (G4): Asymptomatic cases (n = 27).
Patients with liver symptoms (both G1 and G 3) were
then re-classified according to type of hepatic presenta-
tion into:
- Acute hepatitis (AH): d e f i n e da sa c u t eo n s e to f
jaundice and elevated liver enzymes in a previously
apparently healthy subject (n = 6).
- Acute liver failure (ALF): defined as coagulopathy
(INR > 2) with acute onset of jaundice with or with-
out encephalopathy (n = 13).
- Chronic liver disease (CLD): defined as patients
with any form of chronic liver disease (compensated
or decompensated) (n = 20).
Liver function tests and other routine laboratory data
(including viral markers and autoantibodies) were per-
formed using standard methods to evaluate the degree
of liver affection as well as to identify/exclude any asso-
ciated hepatic condition. If not contraindicated due to
severe coagulopathy or advanced refractory ascites, liver
biopsy was obtained (n = 39) before initiation of
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with neurological symptoms
Diagnosis was confirmed by mutational analysis
(sequencing of ATP7B gene) in 64 patients (25 asympto-
matic and 39 symptomatic) (48 of whom were pre-
viously reported in Abdelghaffar et al., 2008 study) [9].
Treatment
￿ Group 1 patients:
- In all patients D-PCA was initiated in incremental
doses, starting with 2-5 mg/kg/day and gradually
increasing the dose every week (after testing the
urine for RBCs and albumin and doing a CBC) to a
maximum of ~20 mg/kg/day in two divided doses
(mean dose was 18 mg/kg/day).
- Zinc sulfate was given (as zinc acetate is not avail-
able in Egypt) in the initial period in a dose of 75
-150 mg/day in two divided doses till the optimal
dose of D-PCA was reached and then gradually
decreased and maintained at a single daily dose of
50-75 mg. Patients were instructed to leave at least 6
hours between the doses of zinc and D-PCA.
Maintenance therapy was started in patients after
becoming clinically well with stable or normal transami-
nases and hepatic synthetic function and 24-hour urin-
ary copper less than 500 μg/day. D-PCA dose was
gradually decreased and then maintained at a dose of
~10 mg/kg/day and zinc dose was maintained at 50- 75
mg/day.
￿ Group 2 and Group 3 patients:
D-PCA was started as in group 1 but maximum dose
reached was lower (maximum 7 mg/kg/day) and zinc
sulfate was given at 150-225 mg/day.
￿ Group 4 patients:
The regimen of group 1 was applied to all asympto-
matic children except three patients who had only ele-
vated liver enzymes and for whom zinc sulfate
monotherapy (given in three daily doses) was used. One
of them was only one year old.
D-PCA was discontinued when serious side effects
occurred, in which case zinc sulfate was the only treat-
ment used. Vitamin E in a dose of 200-400 IU was pre-
scribed to all patients while vitamin B6 was prescribed
to all patients taking D-PCA. All patients were advised
to follow a low-copper diet.
Follow up and compliance
Patients were seen regularly every 7-10 days until the
optimal dose of D-PCA was reached, thereafter every
month for three months then three to four times per
year. In each visit, they were assessed clinically and their
ALT, albumin, INR and CBC were determined, urine
examination was done and drug adverse effects were
checked for. Doppler abdominal U/S and examination
for KF ring were performed every year or as needed.
Compliance was assessed by interviewing the patients
and their parents, regular checking of transaminases and
by yearly assessment of free serum copper and 24 hour
copper in urine. Disappearance of a previous KF ring
and normalization of free serum copper were taken as
evidence of compliance. Non adherence (non compli-
ance) was defined as not taking medication as pre-
scribed associated with increased liver transaminases,
urinary copper or free serum copper (modified after
Arnon et al., 2007) [10].
Statistical methods
The standard computer program SPSS for Windows,
release 13.0 (SPSS Inc, USA) was used for data entry
and analysis. All numeric variables were expressed as
mean ± standard deviation (SD). Comparison of differ-
ent variables in various groups was done using student’s
t test and Mann Whitney test for normal and nonpara-
metric variables, respectively. Multiple regression analy-
sis was also performed to determine effect of various
factors on a dependent variable. Chi-square (c
2) test was
used to compare frequency of qualitative variables
among the different groups. Spearman’s correlation test
was used for correlating non-parametric variables. For
all tests a probability (p), less than 0.05 was considered
significant. Survival statistics was done using the Kaplan
Meire curve [11].
Results
Patients’ features at disease presentation
Mean age of the 75 pediatric patients at disease onset
was 9.92 ± 0.37 years (Median: 10 years, range 1-18
years) (excluding the two adult patients). Parental con-
sanguinity was present in 78.9% of families (table 1).
Leipzig score [12] was retrospectively applied to the
patients: 73 of them had a score of ≥4 and only 4 chil-
dren had a score of less than 4 (two asymptomatic and
two hepatic); none of whom did mutational analysis at
the time of scoring.
Serum ceruloplasmin was <20 mg/dl in 93.5%. Ele-
vated urinary copper excretion was present in 19/25
(84.2%), KF ring was detected in 45/65 (69.2%) and posi-
tive family history of WD was present in 77.8% of
patients (table 2).
The mean age at presentation was 10.96 ± 0.45 years
(Median: 10 years). Patients with hepatic manifestations
(G1) showed earlier onset than those with neurological
manifestations (G2 and G3), (median age of onset = 10,
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cally significant (p = 0.017). Family screening was effec-
tive at diagnosing WD slightly earlier at a median age of
8 years (table 3)
Time lag between onset of the disease and its diagno-
sis was 1.03 ± 0.2 years; it was prolonged in patients
with neurological symptoms (4.75 ± 0.9 years in G2 and
1.9 ± 0.6 years in G3) compared to the hepatic group
(0.83 ± 3 years), a difference which showed a high statis-
tical significance (p = 0.000).
Hepatomegaly was the most common sign present in
asymptomatic patients (being found in 81.5%). It was
present in 62.9% and 55.6% of patients in the hepatic
and combined groups, respectively, but in only 33.3% of
purely neurological cases. Splenomegaly was most com-
mon in G1 (62.9%) and G3 (66.6%). Surprisingly, one
third of asymptomatic patients (33.3%) had
splenomegaly. On the other hand, patients with neurolo-
gical presentation were less likely to have an enlarged
spleen (16.6%).
Jaundice was the most common clinical presentation
in G1 (68.6%), being much less common in G3 patients
( 2 2 . 2 % ) ,w h ow e r em o r el i k e l yt op r e s e n tw i t ha s c i t e s
(44.4%) and lower limb oedema (55.6%). None of the
latter group had hepatic encephalopathy while it
occurred at presentation in 2/35(5.71%) of purely hepa-
tic patients.
Routine liver function tests revealed a significant dif-
ference between different groups. While ALT was high-
est in asymptomatic patients, AST was highest in G1
and G3 patients and lowest in purely neurological cases.
Serum bilirubin and albumin were most deranged in G1
patients. INR was highest in patients with combined
presentation (table 3).
Liver biopsy was performed in 39 patients, identifying
cirrhosis histologically in all biopsies from G3 (4/4) and
nearly two thirds of the G1 patients (7/11). Liver biopsy
was also performed in 20 asymptomatic children of
whom 45% revealed cirrhosis. Half of biopsied patients
with purely neurological disease (2/4) had either chronic
hepatitis or cirrhosis (25% each) (table 3). Thirteen chil-
dren with cirrhosis were ≤ 10 years old (data not shown).
Of all the hepatic patients (G1 and G3), 13/44 (29.5%)
presented with ALF. Male gender predominated in
patients with ALF. Median age of presentation of the
ALF group (9 ± 3 years) was lower than that of AH (11
± 4 years) and CLD (10.5 ± 4 years) (statistically not sig-
nificant). KF ring was present in all tested acute
patients, whether compensated or not. It was also posi-
tive in 19 out of 20 patients with CLD (table 4) and
four of the asymptomatic patients (table 3).
The most common neurological manifestations were
tremors and dysarthria. MRI brain revealed variable
involvement of basal ganglia and cerebellum.
Renal manifestations were noted in 10 patients (renal
stones in 6 patients and nephropathy in 4). Recurrent
urinary tract infections (UTI) were present in 4 patients.
Other extra hepatic manifestations detected in 13
patients were: recurrent abortion in 2 females, gallstones
in 5 patients and arthralgia in 6. Co-morbidities present
in 6 patients included hepatitis A, B, C in three patients
(each had one infection) and bilharziasis in three
patients.
Sequencing of ATP7B gene was performed as pre-
viously described in Abdelghaffar et al. 2008 in 64
patients to genetically characterize this cohort [9]. Mole-
cular genetic characteristics are illustrated in (table 5).
Treatment and follow up
62 of the patients were followed up for a mean period of
58.9 ± 6.4 months (range: 14 days -17 years).
Table 1 Demographic data and type of presentation of
the studied group
Age of onset (years) Range 1-18
Mean ± SD 9.92 ± 0.37
Median ± IR 10 ± 4
Age at presentation (years) Range 1.0 -19
Mean ± SD 10.96 ± 0.45
Median ± IR 10 ± 4
Sex (M/F) 43/34
Consanguinity No. (%) 56/71 (78.9%)
Number of families 50
Residency (73)- No. (%) Upper Egypt 25 (34.2%)
Lower Egypt 30 (41.1%)
Cairo 12 (16.4%)
Non-Egyptian 6 (8.2%)
Type of presentation No. (%) Hepatic 35 (45.5%)
Neurological 6 (7.8%)
Combined 9 (11.7%)
Asymptomatic 27 (35.1%)
N.B. Two adult patients with ages of 30 and 37 years (cousins of one of the
children) were excluded when calculating the age ranges and mean.
M: male, F: female, SD: standard deviation, IR: interquartial range
Table 2 Criteria used in diagnosis of WD in the studied
group
No. %
S. Ceruloplasmin (mg%) ≤ 7 57/77 74
7-20 15/77 19.5
>2 0 5/77 6.5
Positive Family history 56/72 77.8
K F ring 45/65 69.2
Elevated urinary copper excretion 19/25 84.2
Liver biopsy suggestive of WD 15/39 38.5
Coomb’s negative hemolytic anemia 4/74 5.4
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16 out of the 52 patients on long-term chelation
(30.76%) (6 patients from G1, 3 from G2, 5 from G3
and 2 from G4). Hematuria was the commonest side
effect occurring in 9 patients. It was accompanied by
albuminuria in 3 patients. Deterioration of neurological
symptoms occurred in 3 patients (one of whom was
pregnant). Two patients developed leucopenia, while an
allergic skin reaction, thrombocytopenia, loss of hair
and itching occurred in one patient each.
D-PCA had to be completely discontinued in only 6
patients (11.5%). Four of them (three from the same
family) developed progressive hematuria and albumi-
nuria while in the other two, marked deterioration of
neurological symptoms occurred. The rest of the side
effects reverted by decreasing the dose of D-PCA.
Zinc sulfate as monotherapy was used in 9 patients (in
3 asymptomatic and in the 6 for whom D-PCA had to
b ed i s c o n t i n u e d ) .T h eo n l ys i d ee f f e c t sn o t e dw e r e
vomiting and epigastric pain, which improved when zinc
was taken with little protein.
Six patients successfully conceived (5 from G4 and 1
from G3). Treatment was switched during pregnancy to
zinc sulfate. Four had normal babies. One developed
neurological manifestations during pregnancy. She was
non-compliant on zinc and delivered a girl in whom
Budd-Chiari syndrome was diagnosed at the age of 6
months. One patient delivered a baby with Fallot’st e t -
ralogy. She was already on zinc sulfate as a sole treat-
ment when she got pregnant but she was scarcely
adherent to therapy. Another stopped treatment after
delivery and this was followed by recurrent abortions.
Table 3 Comparison between different studied groups as regards clinical and laboratory data
G1 (35) G2 (6) G3 (9) G4 (27) Total (77) P value
Male/Female 20/15 4/2 7/2 12/15 43/34 0.32
Median age of onset (yrs) (Range) 10 (6-15) 12 (10-14) 11 (9-18) 8 (1-17) 10 (1-18) 0.017 *
Duration between onset and diagnosis (yrs) 0.83 ± 3 4.75 ± 0.9 1.9 ± 0.6 - 1.03 ± 0.2 0.000*
Duration of follow up (ms) Mean (Range) 60.27 (0.25-156) 32.5 (12-48) 75.86 (12-156) 89.55 (5-156) 58.9 (0.25-156)
S. Ceruloplasmin <7 25 (71.4) 6 (100) 7 (77.8) 19 (70.4) 57 (74)
(mg%) 7-20 6 (17.1) 0 (0) 2 (22.2) 7 (25.9) 15 (19.5)
No. (%) >20 4 (11.4) 0 (0) 0 (0) 1 (3.7) 5 (6.5)
Hepatomegaly 22 (62.9) 2 (33.3) 5 (55.6) 22 (81.5) 51 (66.2) 0.134
Hepatic Splenomegaly 22 (62.9) 1 (16.6) 6 (66.6) 9 (33.3) 38 (49.4) 0.006
signs Jaundice 24 (68.6) 0 (0) 2 (22.2) 0 (0) 26 (33.8) 0.000*
No. (%) Ascites 17 (48.6) 0 (0) 4 (44.4) 0 (0) 21 (27.3) 0.000*
LL Oedema 15(42.9) 0 (0) 5(55.6) 0 (0) 20 (26) 0.000*
Encephalopathy 2 (5.7) 0 (0) 0 (0) 0 (0) 2 (2.6)
ALT (x ULN) 2.8 ± 0.4 1.7 ± 0.8 1.7 ± 0.3 3.2 ± 0.5 2.7 ± 0.3 0.056
Liver AST (x ULN) 3.9 ± 0.5 1.0 3.9 ± 0.2 2.4 ± 0.3 3.2 ± 0.3 0.001*
function Bilirubin (mg%) 8.0 ± 1.7 2.5 ± 1.6 1.8 ± 0.5 0.8 ± 0.1 4.2 ± 0.8 0.000*
tests Mean ± SD INR 3.0 ± 0.4 1.3 ± 0.2 3.8 ± 0.2 1.1 ± 0.04 2.3 ± 3.4 0.000*
Albumin (gm%) 2.6 ± 0.1 4.3 ± 0.1 3.0 ± 0.3 3.9 ± 0.2 3.2 ± 1.2 0.000*
Chronic hepatitis 4/11 (36.4) 1/4 (25) 0/4 (0) 7/20 (35) 12/39 (30.8)
Liver Cirrhosis 7/11 (63.6) 1/4 (25) 4/4 (100) 9/20 (45) 21/39 (53.8)
biopsy Steatosis 3/11 (27.3) 1/4 (25) 2/4 (50) 2/20 (10) 8/39 (20.5)
No. (%) Glycogenated nuclei 2/11 (18.2) 1/4 (25) 0/4 (0) 7 (35) 10/39 (25.6)
Cu associated protein 4/11 (36.4) 0/4 (0) 1/4 (25) 5 (25) 10/39 (25.6)
Pigment 1/11 (9) 1/4 (25) 0/4 (0) 2 (10) 4/39 (10.3)
Positive KF rings No. (%) 27/28 (96.4) 6/6 (100) 8/8 (100) 4/23 (17.4) 45/65 (69.2) 0.000
Table 4 Comparison between different types with hepatic
involvement (G1 and G3)
Chronic
LD
Acute
hepatitis
ALF P
value
No. (%) 25/44
(56.8)
6/44 (13.6) 13/44
(29.5)
Male/Female 13/12 3/3 11/2 0.178
Age range (yrs) 6-15 9-15 6-13
Mean age (yrs)± SD 10.7 ± 2.8 11.57 ± 2.15 9.33 ±
2.01
1.49
Median age (yrs) ±
IR
10.5 ± 4 11 ± 4 9 ± 3
Positive KF ring No.
(%)
19/20
(95%)
6/6 (100) 10/10
(100)
0.276
SD: standard deviation, IR: interquartial range, KF: Kayser-Fleisher
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76.1% of the patients were compliant to therapy; compli-
ance did not significantly differ in relation to the type of
presentation (data not shown). Non-compliance increased
with increasing age (figure (1). Kaplan Meier curve showed
a significant effect of compliance on survival (figure 2).
Treatment outcome
One patient out of the 62 was lost to follow up and 6
patients (5 males and 1 female) died within two weeks
of presentation due to fulminant hepatitis. Forty-one out
of the remaining 55 patients (74.5%) had a stable or
improved course while four patients got worse; two of
Table 5 Homozygous mutations detected in children with Wilson disease in this study
Mutation Type of mutation No. of
patients
No. of
chromosomes
Form of WD
c.507delA, p.Gly170fs* deletion/frameshift 1 2 H (CLD)
c.1186G > T, p.Glu396X* Nonsense 3 6 2 C (CLD)
N
c.330delA, p.Gln110fs* deletion/frameshift 2 4 C (CLD)
c.1646T > C, p.Leu549Pro* Missense 1 2 C (CLD)
c.1707+5G > A, IVS4+5G > A*
1 Splice 2 4 2 C (CLD)
c.1924G > C, p.Asp642His Missense 1 2 H (CLD)
c.2108G > A, p.Cys703Tyr Missense 2 4 H (CLD)
H (ALF)
c.2304dupC, p.Met769fs insertion/frameshift 1 2 A
c.2293G > A, p.Asp765Asn Missense 1 2 H (CLD)
c.2532delA, p.Val845fs deletion/frameshift 2 4 H (CLD)
c.2993G > A, p.Gly998Asp* Missense 1 2 Combined
c.2930C > T, p.Thr977Met
1 Missense 2 4 H (CLD)
c.2997dupC, p.Gly1000fs insertion/frameshift 1 2 H (ALF)
c.3207C > A, p.His1069Glu Missense 3 6 H (CLD)
c.3373_3377delAGTCAinsTCT, p.His1126fs* deletion-insertion/frameshift 4 8 H (CLD)
c.3620A > G, p.His1207Arg
1 Missense 1 2 A
c.3904-2A > G, IVS18-2A > G Splice 4 8 H (ALF)
C (CLD)
H (CLD)
C (CLD)
c.3809A > G, p.Asn1270Ser Missense 2 4 C (CLD
c.3818C > T, p.Pro1273Leu Missense 3 6 H (CLD)
c.3731delT, p.Leu1244fs* deletion/frameshift 1 2 H (ALF)
c.3994A > G, p.Asn1332Asp* Missense C (CLD)
c.3955C > T, p.Arg1319X Nonsense 3 6 H (ALF) H
(CLD)
c.4021G > C, p.Gly1341Arg* Missense 2 4 H (CLD)
c.4022G > A, p.Gly1341Asp Missense 1 2 H (CLD)
c.4301C > T, p.Thr1434Met Missense 1 2 C (CLD)
c.4230G > A, p.Trp1410X* Nonsense 1 2 H (CLD)
c.3734G > T, p.1245L Missense 1 2 C (CLD)
c.3188C > T, p.Ala1063Val Missense 1 2 N
H (CLD)
c.2049_2053delCCTGGinsTTTC, p.
Val683_Leu684delinsVal
deletion-insertion/frameshift 1 2 H (ALF)
c.2332C > G, p.Arg778Gly Missense 2 4 H (CLD)
c.2450delA, p.Glu817fs deletion/frameshift 1 2 C (CLD)
IVS20+6T > C Splice 1 2 C (CLD)
c.2231T > C, p.S744P Missense 1 2 H (CLD)
1Suspected disease causing variants
(*): novel mutations detected in this study
*genbank sequences (NM_000053.2)
A: asymptomatic, H: hepatic, N, neurological, C: combined, AH: acute hepatitis, CLD: chronic liver disease. ALF: acute liver failure
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Page 6 of 11them were asymptomatic at diagnosis. Worsening was in
the form of developing neurological symptoms or dete-
rioration of liver disease, all four were non-compliant to
therapy. Late mortality occurred in 10 patients (6 males,
3 females) (18.2%).
Treatment outcome of asymptomatic patients
Of the 22 asymptomatic patients who were followed up,
1 9h a de i t h e ras t a b l e( 5 )o ra ni m p r o v e dc o u r s ea s
regards liver enzymes (14) while 2 patients got worse
due to non-compliance (one developed severe neurologi-
cal manifestations, and the other had deterioration of
liver disease). Outcome in relation to different groups is
presented in table (6).
Overall mortality
Sixteen patients died in the course of disease. Early
death due to ALF occurred in 6 patients and late death
in 10 patients (decompensated cirrhosis in 7, bleeding
esophageal varices in one patient and sepsis in two
patients). Using the prognostic score proposed by Dha-
wan et al., 2005 [8], all patients with early death had a
score of ≥ 11 while only one patient with late death had
ap r o g n o s t i cs c o r eo f≥ 11 at presentation, figure (3).
Yet, 2 out of 8 patients who had a prognostic score > 11
at presentation responded well to chelation therapy. Late
death was significantly related to compliance.
Mutational analysis
Sequencing of the ATP7B gene was performed in 65
patients. Mutations within the gene were identified in
64 of them and in only one patient no mutations were
detected (he was excluded from the study). Eleven
mutations were novel (table 5). Fifty four patients
(85.7%) had homozygous mutations while only 9 (14.3%)
were compound heterozygous. For better genotype-phe-
notype analysis, only homozygous mutations were con-
sidered for further analysis:
- 25 patients (46.3%) had missense, 14 had frame-
shift (25.9%), 8 had nonsense (14.8%) and 7 had
splice site mutations (12.9%).
- Mean age of onset in patients with protein-truncat-
ing mutations was 9.9 years while that in patients
with missense mutations was 10.46 years.
- 37.9% (11/29) of patients with protein-truncating
mutations were ≤ 8 years compared to 32% (8/25) of
patients with missense mutations.
- Death occurred in 17.2% (5/29) of patients with
protein-truncating mutations compared to only 8%
(2/25) of patients with missense mutations. Patients
Figure 1 Scatter chart showing that non compliance increased
with increasing age.
Figure 2 Kaplan Meier curve showing a significant effect of
compliance on survival (Blue line: non-compliance < 50% of
follow up time. Red line: non-compliance ≥ 50% of follow up
time).
Table 6 Outcome of the studied patients
G1 (27) G2 (4) G3 (8) G4 (22) Total (61)
Stationary 2 1 3 5 11 (18%)
improved 11 2 3 14 30 (49.2%)
worse 2 0 0 2 4 (6.5%)
Early death 6 0 0 0 6 (9.8%)
Late death 6 1 2 1 10 (16.4%)
Abdel Ghaffar et al. BMC Pediatrics 2011, 11:56
http://www.biomedcentral.com/1471-2431/11/56
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ALF (4/5).
- Six out of 10 homozygous patients with ALF had a
mutation resulting in a truncated protein (frameshift
(40%), nonsense (10%) or splice site mutation (10%).
Death occurred in 4 out of these 6 (66.6%) com-
pared to only one out of the other 4 with missense
mutations (25%)).
- 70% of patients who presented or eventually devel-
oped neurological symptoms had a protein-truncat-
ing mutation (25% splice site, 20% frameshift, 25%
nonsense).
- Splice site mutations were present in 7 patients, 5
of them eventually developed neurological symptoms
- The most common mutation found was c.3904-2A
>G ,I V S 1 8 - 2 A>G ,w h i c hw a sf o u n di n5p a t i e n t s ,
3 of them were from the same family. This was fol-
lowed by c.3373_3377delAGTCAinsTCT, p.
His1126fs, which was found in 4 patients from the
same family and c.3207C > A, p.His1069Glu, which
was also found in 4 patients, 3 of them from the
same family.
Discussion
In this cohort of children with WD who are mostly
Egyptians, there are a number of diagnostic and clinical
features, which differ from those previously reported in
the Western literature. The KF ring, which in absence
of chronic cholestasis is the best diagnostic sign of WD,
has been found in 96.4% of our children with purely
hepatic manifestations. All patients with acute hepatitis
as well as all patients with ALF had a KF ring. Further-
more, it was found in 17.4% of asymptomatic siblings.
These figures are substantially higher than those
reported in children with hepatic WD. Merle et al., 2007
reported the presence of a KF ring in 66.3% of their
pediatric cohort. In most other studies, a KF ring was
present in less than 50% of the patients [3,8,13]. The
youngest child in this cohort positive for KF ring was
only 6 years old. Although this high frequency of KF
ring could indicate early onset of neurological disease,
the possibility of environmental exposure to excessive
amounts of copper could not be ruled out.
Only 6.5% of our patients had normal ceruloplasmin.
Dhawan et al., 2005 found a normal ceruloplasmin in
20% of their pediatric cohort [8]. It seems thus that
within this cohort, it is very uncommon to find sympto-
matic patients negative for KF ring and having a normal
ceruloplasmin level, suggesting that the value given to
different items in the Leipzig score might have to be
modified for different ethnic groups.
Coomb’s negative hemolytic anemia occurred at pre-
sentation in only 5.4% of patients, a percentage that is
much less than that reported by Walshe 1987 (11%) [14],
and slightly more than in Japanese patients (1.2%) [4].
Although in this study urinary copper excretion before
and after D-PCA challenge yielded results diagnostic of
WD in 84.2% of patients, it was performed in only 25
patients in this cohort, thus revealing the difficulty in
obtaining accurate 24 hour urine collection for performing
this test in children and confirming previous reports [8].
Other features characteristic of this pediatric cohort
was the low age of onset of the disease. Median age of
onset in our children was 10 years. Previous studies
reported an onset of 12.2 years in Japan, 11 ± 7 years in
Iran and 7.2 years in India [15-17]. This finding may
suggest that Egyptians may have an early age of onset of
WD. Whether this finding is related to the effect of
environmental factors or to polymorphisms in the
MURR1 gene needs further studies.
While cirrhosis is frequently found in most patients
with WD by the second decade of life [18], in our study
almost two thirds of cirrhotic patients were ≤ 10 years
old (13/21). In addition, 45% of asymptomatic children
were already cirrhotic at the time of diagnosis (as con-
firmed by liver biopsy) with their median age being only
8 years. The youngest patient with cirrhosis in this
cohort was only 7 years old. Ascites was present at pre-
sentation in more than half of the patients with liver
symptoms. Again, a figure higher than that reported in
other studies [4,19]. This implies that the hepatic disease
runs a more aggressive course in the Egyptian children a
finding that might be related to genetic factors, undeter-
mined environmental factors or gene modifiers.
Co-existence of WD and viral infections may lead to
early onset, severe presentation and rapidly progressive
liver disease [20]. True co-morbidity of WD at the time
Figure 3 Kaplan Meier curve showing a significant effect of
Dhawan et al [8]prognostic score on survival (red line:
prognostic score ≥11. blue line: prognostic score <11)
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expected by chance [21]. It is to be noted that in this
study the three patients who had schistomiasis ran a
detrimental course (one died, one developed neurologi-
cal symptoms and the last had deterioration of his liver
functions). To the best of our knowledge, the effect of
schistomiasis on the course of WD has not been
reported before.
Due to the high incidence of consanguineous marriage
(78.9%) and the extended family size in our community,
asymptomatic siblings constituted 35% of this cohort,
thus allowing for studying the disease in its presympto-
matic phase. Most of those children (81.5%) had hepato-
megaly, one third had splenomegaly (37.5%) and the
only disturbed LFTs were ALT/AST. In spite of being
asymptomatic, yet histologically evident cirrhosis was
present in 45% and a KF ring was detected in 17.4%.
The youngest affected sibling was only one year old.
This emphasizes the need for screening of all sibs of
affected children even at a younger age than previously
recommended.
Nearly one third of the patients (29.5%) with hepatic
manifestations presented with ALF. A slightly higher
percentage was reported by Dhawan et al. (33%) [8], yet,
lower figures were reported in other studies [22]. Again,
the age of onset of patients with ALF in this cohort
(median: 9 years) is less than generally reported. In our
cohort as well as that of Dhawn et al., there was a male
predominance. This is in contrast to previous reports
where females were more commonly represented among
WD patients with ALF [21]. It has been suggested that
the female predominance was due to the effect of sex
hormone as shown in the animal model of WD [23].
Dhawan et al. attributed these contrasting results to the
fact that most of their patients were prepubertal, which
holds true for our group of patients as well [8].
In this study, as in others [8,24-27], D-PCA has been
shown to be an effective copper chelator in both symp-
tomatic and asymptomatic WD patients who are com-
pliant to treatment.. Side effects were observed in
30.76% and were severe enough to discontinue the drug
in 11.5%. Such figures are slightly less than those
reported by others for both adults [3] and children
[8,28]. In Egypt, the only available decoppering agent is
D-PCA, so we tried hard to limit its side effects by start-
ing therapy with a very small dose that was very gradu-
ally increased to reach the maximum desired dose
meanwhile giving zinc sulphate starting with a maximal
dose and gradually reducing it as D-PCA was increased.
O ft h ec h i l d r e nb o r nt oW Dm o t h e r so n es u f f e r e d
from Fallot’s tetralogy and another was diagnosed as
Budd-Chiari syndrome at 6 months of age. In both
cases, the mother did not receive D-PCA during preg-
nancy and they both were totally non-compliant on zinc
therapy. This may implicate intrauterine exposure to
excess copper, a teratogenic substance, as the cause in
both children.
Zinc monotherapy has been shown to be an effective
non-toxic alternative to D-PCA in asymptomatic siblings
[29]. It was approved in 1997 by the US FDA as mainte-
nance therapy. Yet some reports indicate its efficacy also
as first line treatment of symptomatic patients [7].
Three of the asymptomatic children in this study have
been effectively treated with zinc monotherapy. It was
also used in the six patients for whom D-PCA had to be
discontinued and in all it was effective. The mechanism
of action of Zinc is different from that of D-PCA as it
inhibits copper absorption by inducing enterocyte metal-
lothionin. It may also induce hepatocyte metallothionin
[30] and can generate a negative balance for copper
thereby removing stored copper [31]. We used the com-
bination of Zinc sulphate (a single midday dose) and D-
PCA for our patients, spacing them at least 6 hours
apart. Although the use of a single midday zinc sulfate
dose decreases the chance of non compliance, its effec-
tiveness in the production of a negative copper balance
is uncertain.
S i xp a t i e n t si nt h i ss e r i e sd i e dw i t h i nt w ow e e k so f
presentation. They all had a score >11 in the new Wil-
son predictive index proposed by Dhawan et al. 2005.
None of the patients with score <11 experienced early
death, yet two patients with a score >11 survived on
medical management without transplantation. In their
original description of the score, Dhawan et al. 2005
indicated that a score >11 was predictive for death with
a sensitivity of 93%, specificity of 98% and positive pre-
dictive value of 88% [8].
During follow up ten patients died, in six of whom
death resulted from hepatic decompensation. All six
were non-adherent to therapy. The adverse effect of
non- compliance to therapy on survival has been clearly
demonstrated in the Kaplan Meier survival curve. Nearly
24% of our patients were non adherent to therapy more
than 50% of the time. Brewer et al. (1994) found that
about 10% of the patients had serious non adherence
problems and another 20% had episodic non adherence
when followed up for 5-10 years [29]. Arnon et al.
(2007) reported that poor adherence to therapy might
be responsible for the persistence of elevated ALT [10].
The patients in this study who developed liver decom-
pensation could not be rescued since liver transplanta-
tion became available in Egypt only since late 2001.
Homozygous mutations were present in 54 patients
(85.7%). This high percentage may be explained by the
high percentage of consanguinity in our study (78.9%)
compared to the consanguinity in the Egyptian popula-
tion (32-35%) [32]. In spite of the high percentage of
homozygous mutations, it was difficult to find genotype-
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mutations detected. Heterogeneity of the Egyptian popu-
lation with respect to ethnicity may justify the presence
of such big number of different mutations that may also
reflect a high carrier rate for WD in our population.
Protein truncating mutations profoundly affect gene
functions [27,33]. Patients with protein-truncating muta-
tions in this study had slightly earlier age of onset, died
earlier from ALF and neurological symptoms were more
common among them.
Conclusions
Egyptian children with WD present with early KF rings,
and early onset of liver and neurological disease. The
mutation spectrum identified differs from that observed
in other countries. This study offers screening strategies
f o rW Di nE g y p t ,w h i c hm a yn o td e p e n do ng e n e t i c
testing.
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